. Here, we show that in LCLs, RA inhibits ubiquitination and proteasomedependent degradation of p27 Kip1 , a phenomenon that is associated with downregulation of Thr187 phosphorylation of the protein, whereas the phosphorylation on Ser10 is unaffected. Furthermore, we demonstrate that RA downregulates the expression of the p45 Skp2 and Cks1 proteins, two essential components of the SCF Skp2 ubiquitin ligase complex that target p27
Kip1 for degradation. Downregulation of p45 Skp2 and Cks1 occurs before the onset of growth arrest and is due to enhanced proteasome-mediated proteolysis of these proteins. Moreover, overexpression of p45
Skp2 in DG75 cells prevents p27 Kip1 protein accumulation and promotes resistance to the antiproliferative effects of RA. Treatment with Leptomycin B (LMB) blocked the translocation of p27
Kip1 to the cytoplasm and prevented its degradation, indicating that CRM1-dependent nuclear export is required for p27
Kip1 degradation. The shuttle protein p38 Jab1 , however, does not accumulate in the nucleus upon LMB treatment, nor does it interact with p27 Kip1 . Conversely, p45 Skp2 is associated with p27
Kip1 both in the nucleus and in the cytoplasm, accumulating within the nuclei after exposure to LMB and co-localizing with the exportin CRM1, suggesting a possible involvement of p45 Skp2 in CRM1-dependent nuclear export of p27 Kip1 . These results indicate that downregulation of p45
Skp2 is a key element underlying RA-induced p27
Kip1 stabilization in B cells, resulting in an impaired targeting of the protein to the ubiquitin-proteasome pathway and probably contributing to the nuclear accumulation of p27
Introduction
Retinoids are a group of natural derivatives and synthetic analogs of vitamin A that play crucial roles in regulating the proliferation and differentiation of a variety of cell types. In particular, retinoids can suppress the process of tumorigenesis both in vitro and in vivo, and treatment with retinoic acid (RA) may inhibit cell growth and induce arrest in the G 1 phase of the cell cycle. Recent evidence indicates that retinoids may accomplish these effects through direct modulation of the levels of cell cycle regulatory proteins. In fact, these compounds may interfere with cell cycle regulation by enhancing cyclin D1 and cyclin E proteolysis (Langenfeld et al., 1997; Boyle et al., 1999) . Moreover, treatment of human embryonal carcinoma cells with all-trans-RA induced G 1 arrest through the accelerated ubiquitination of cyclin D1 (Spinella et al., 1999) . Besides regulating the turnover of cyclins, retinoids were also shown to exert antiproliferative effects by modulating the levels of cyclin-dependent kinase (CDK) inhibitors, particularly of p21 WAF1/CIP1 (Liu et al., 1996; Li et al., 1998; Suzui et al., 2002) and p27
Kip1 (Pomponi et al., 1996; Zancai et al., 1998; Baldassarre et al., 2000; Hsu et al., 2000; Dow et al., 2001; Zhang et al., 2001; Dimberg et al., 2002) . Nevertheless, the molecular mechanisms underlying these effects are still poorly defined.
The CDK inhibitor p27 Kip1 mediates several antimitogenic signals through inhibition of the protein kinases CDK2/cyclin E and CDK2/cyclin A, which promote the transition from the G 1 to the S phase of the cell cycle (Slingerland and Pagano, 2000) . p27
Kip1 is regulated by both transcriptional and post-transcriptional mechanisms with proteasome-dependent degradation of the protein being a major determinant of intracellular levels of p27
Kip1 (Bloom and Pagano, 2003) Understanding the mechanisms of p27
Kip1 degradation is of considerable importance, as destabilization of p27 Kip1 occurs in many aggressive human cancers and therefore agents able to promote p27
Kip1 stabilization are of major therapeutic interest. Available evidence indicates that ubiquitination and degradation of p27
Kip1 require its phosphorylation on Thr187 by the CDK2/cyclin E kinase (Muller et al., 1997; Sheaff et al., 1997; Vlach et al., 1997; Montagnoli et al., 1999; Tsvetkov et al., 1999) . Degradation of p27
Kip1 is also dependent on the SCF Skp2 (Skp1-Cullin 1-F box protein) E3 ligase complex, which is involved in recognizing and targeting phosphorylated proteins for ubiquitination Sutterluty et al., 1999; Tsvetkov et al., 1999; Nakayama et al., 2000; Ganoth et al., 2001; Spruck et al., 2001) . p45
Skp2 (Sphase kinase-associated protein 2) has been recently identified as a candidate receptor component of the E3 ligase complex that binds to phosphorylated p27
Kip1 and promotes ubiquitination and degradation of the protein . Ectopic expression of p45
Skp2 in quiescent cells stimulates entry into the S phase of the cell cycle and promotes ubiquitination of p27 Kip1 , indicating that the amount of p45
Skp2 is rate limiting for p27
Kip1 degradation (Sutterluty et al., 1999) . In normal cells, expression of p45
Skp2 is restricted to the S phase (Zhang et al., 1995; Lisztwan et al., 1998) , suggesting that regulation of p45
Skp2 expression is a further mechanism that contributes to the correct timing of p27
Kip1 degradation. Recent data also indicate that Cks1, another component of the SCF Skp2 complex, is essential for p27
Kip1 ubiquitination due to its ability to enhance binding of Thr187-phosphorylated p27
Kip1 to p45
Skp2 (Ganoth et al., 2001 ). The activity of p27
Kip1 is also dependent on its subcellular localization. In fact, the growth-restraining function of p27
Kip1 requires the presence of the protein within the nucleus where it interacts with and inhibits target cell cycle proteins. A nuclear localization signal located in the C-terminus of p27
Kip1 is thought to be responsible for the transport of p27
Kip1 into the nucleus (Reynisdottir and Massague, 1997; Tomoda et al., 1999) . Recent findings have demonstrated that transportation of p27
Kip1 from the nucleus to the cytoplasm is crucial for proteasome-mediated degradation of the protein. In particular, p38 Jab1 , a component of the COP9 signalosome complex, was shown to directly interact with p27
Kip1 and promote its nuclear export by a mechanism involving the Chromosomal region maintenance-1 (CRM1) carrier protein (Tomoda et al., 1999 (Tomoda et al., , 2002 . The p38 Jab1 -mediated relocalization of p27 Kip1 is necessary for the breakdown of the protein, as mutants of p27
Kip1 unable to bind to p38 Jab1 are neither exported from the nucleus nor degraded by the proteasome (Tomoda et al., 1999 (Tomoda et al., , 2002 . Although phosphorylation of p27
Kip1 on Ser10 seems to be required for CRM1-dependent nuclear export of the protein (Ishida et al., 2002) , the signals mediating the shuttling of p27
Kip1 from the nucleus to the cytoplasm are largely unknown.
Our previous work showed that 9-cis-RA, 13-cis-RA and ATRA exert strong antiproliferative activity in Epstein-Barr virus (EBV)-immortalized lymphoblastoid B cell lines (LCLs), a suitable in vitro model for EBVrelated lymphoproliferative disorders of immunosuppressed patients (Pomponi et al., 1996; Zancai et al., 1998) . In these cells, RA induces a marked upregulation of p27 Kip1 , leading to inhibition of CDK2, CDK4, CDK6 kinase activity and ultimately resulting in reduced pRb phosphorylation and G 0 /G 1 growth arrest (Pomponi et al., 1996; Zancai et al., 1998) . Similar findings were also observed in LCLs carrying a constitutively activated c-myc oncogene, indicating that RA is effective in inhibiting the proliferation also of immortalized B cells that have undergone a further step towards the malignant phenotype (Cariati et al., 2000) . On these grounds, and considering the central role of p27
Kip1 in mediating the antiproliferative activity exerted by RA on EBV-immortalized and neoplastic B lymphocytes, we have carried out a study aimed at defining the mechanisms by which RA upregulates p27
Kip1 in the B cell lineage. Elucidation of these issues is of relevance not only to better understand how RA affects cell cycle machinery in B lymphocytes but also to evaluate more thoroughly the therapeutic potential of RA in the management of B cell lymphoproliferative disorders.
Results

RA upregulates p27
Kip1 by inhibiting proteasome-mediated degradation of the protein To determine the mechanism underlying RA-induced p27
Kip1 upregulation, HDE-14 and DAA-3 cells were treated with the proteasome inhibitors lactacystin blactone and LLnL for up to 8 h. As shown in Figure 1a , both proteasome inhibitors induced an increase of p27
Kip1 expression similar to that observed in cells treated with 13-cis-RA. No relevant additive effect was observed in cells co-treated with 13-cis-RA and LLnL, suggesting that these compounds probably increase p27
Kip1 protein levels by acting on a common target: the ubiquitin/proteasome degradation pathway. We then evaluated the ability of extracts from HDE-14 cells cultured in the presence or absence of 13-cis-RA to degrade recombinant p27 Kip1 in vitro. Analysis of the kinetics of p27
Kip1 degradation over a time course of 6 h showed that 50% of recombinant p27
Kip1 was degraded in about 50 min by extracts from control cultures, whereas proteasome-mediated degradation of the same amount of p27
Kip1 by extracts of RA-treated cells required about 4.5 h (Figure 1b) . Control experiments, carried out preincubating the extract from growing cells with the proteasome inhibitor MG132, showed the absence of p27
Kip1 removal, confirming that the degradation requires MG132-sensitive proteolytic systems. These findings are consistent with the possibility that RA-treated cells may lack some components of the p27 Kip1 proteolytic pathway.
RA inhibits p27
Kip1 ubiquitination and reduces the phosphorylation on Thr187
To verify whether RA affects p27
Kip1 phosphorylation, lysates from 13-cis-RA-treated HDE-14 cells were immunoprecipitated with anti-p27
Kip1 antibody, separated on highly resolutive gel (16 cm) and analysed by immunoblotting with anti-pThr-187 and anti-pSer10 antibodies. As shown in Figure 2a , despite an increase in the total amount of p27 Kip1 , the content of pThr187-p27
Kip1 did not increase concomitantly in response to RA treatment. In contrast, analysis of Ser10 phosphorylation showed that RA did not affect the levels of pSer10-p27
Kip1 that increased proportionally to total p27
Kip1 in the nucleus of treated cells (Figure 2b ). Similar findings were obtained with the DAA-3 LCL (not shown). As a further approach, the phosphorylation pattern of p27
Kip1 including both serine and threonine was analysed using a more resolutive 2D-IEF. In HDE-14 and DAA-3 cells, at least five different p27 Kip1 isoforms could be reproducibly distinguished (four separate experiments were performed in both LCLs) by 2D-IEF using an immobilized nonlinear gradient (pH 3-10) (Figure 2c ). Two major (1 and 3) and three minor isoforms (2, 4 and 5) were detected in both RA-treated and untreated cells. Only a slight decrease of isoform 4 was observed after RA treatment (Figure 2c ). Phosphatase digestion identified isoform 1 as the unphosphorylated p27
Kip1 protein, whereas Western blotting with anti-pSer10 antibody identified isoform 3 as the pSer10-p27 Kip1 ( Figure 2c ). As a control, p27 Kip1 isoforms were also analysed by 2D-IEF in cells treated with the MAPK inhibitor UO126, which has been recently shown to modulate the 2D pattern of p27
Kip1 (Delmas et al., 2003) . The analysis showed a marked downregulation of isoform 1 in cells treated with UO126 (Figure 2c ). Overall, these data indicate that RA-induced p27 Kip1 stabilization is associated with a decreased phosphorylation on Thr187, whereas the phosphorylation on Ser10 is unchanged.
We therefore asked whether the RA-induced p27
Kip1
upregulation was related to a loss of the ubiquitination of the protein. p27 Kip1 was then immunoprecipitated from both 13-cis-RA-treated and control HDE-14 cells, and both cultured with LLnL to increase the half-life of ubiquitinated intermediates and analysed by In vitro degradation assay. Cell extracts were prepared from HDE-14 cells treated for 72 h with 13-cis-RA or 0.01% DMSO as described in Materials and methods. In vitro translated p27
Kip1 protein was added to 60 mg of cell lysates in the presence of ATP regenerating system, incubated at 371C and aliquots were taken at the indicated times. Samples added with the proteasome inhibitor MG132 or its vehicle (DMSO) and p27 Kip1 protein alone were used as controls. The levels of the p27 Kip1 protein were analysed by immunoblotting and quantified by densitometric scanning. The experiments were repeated three times and a representative one is shown. (c) The cell extracts used for the in vitro degradation assay are mainly cytoplasmic, as indicated by the presence of tubulin and the absence of pRb. HDE14 total cell lysate (c) and cell extracts prepared for in vitro degradation assay (DMSO and RA) were analysed by immunoblotting for cytoplasmic protein b-tubulin and nuclear protein pRb Kip1 phosphorylation. (a) HDE-14 cells were treated with DMSO (NT) or 13-cis-RA for 72 h, and a total of 500 mg protein lysate was immunoprecipitated with antip27
Kip1 antibody and immunoblotted with anti pThr187 and pSer10. (b) HDE-14 cells were treated with DMSO (NT) or 13-cis-RA for 72 h and 100 mg of nuclear and cytoplasmic fractions was analysed by immunoblotting with the indicated antibodies. Localization of nucleus-specific protein topoisomerase II (topo II) and cytoplasm-specific tubulin was carried out to confirm the purity of the nuclear and cytoplasmic fractions. (c) 2D-IEF analysis. p27
Kip1 was immunoprecipitated from 200 mg of lysates of HDE-14 cells treated with DMSO or 13-cis-RA for 72 h and resolved using IEF strips with a nonlinear gradient of pH 3 to 10, followed by BIS-TRIS 4-12% gradient gel electrophoresis. After blotting onto nitrocellulose membrane, p27
Kip1 isoforms were detected by immunoblotting with an anti-p27
Kip1 antibody (panels 1 and 2) and anti-pSer10 antibody (panels 5 and 6). Panels 3 and 4: p27
Kip1 immunoprecipitated from HDE-14 cells was subjected to phosphatase treatment prior to 2D-IEF. Results of one representative experiment of four are shown. The results of the same analysis carried out with the MEK inhibitor UO126 (20 mM for 24 h) are included as a control (panel 7) Retinoids promote Skp2 and Cks1 degradation in EBV þ B cells P Zancai et al immunoblotting. While proteasome inhibition caused a marked increase in slowly migrating p27
Kip1 derivatives in control HDE-14 cells, 13-cis-RA-treated cells showed undetectable levels of ubiquitinated derivatives ( Figure 3a ). The analysis of the same p27 
RA stabilizes p27
Kip1 by enhancing proteasome-mediated degradation of p45
Skp2 and Cks1 proteins To elucidate the mechanism by which RA inhibits p27 Kip1 ubiquitination, we investigated whether RA modulates the expression levels of components of the SCF Skp2 ubiquitin E3 ligase complex. Analysis of HDE-14 and DAA-3 cell extracts showed that 13-cis-RA induced an almost complete downregulation of the substrate-targeting subunit p45
Skp2 and its cofactor Cks1, whereas the expression of other components of the SCF complex, p19
Skp1
, and Cul-1, remained unchanged ( Figure 4a ). Of note, RA-induced p45 Skp2 and Cks1 downregulation was evident since 12 h of treatment whereas the levels of p27
Kip1 increased at later time points (after 24 h) ( Figure 4b ). Analysis of p45
Skp2 and Cks1 mRNA expression by Northern blotting over a 3-day time course failed to reveal any significant RAinduced change in the endogenous mRNA levels of both p45
Skp2 and Cks1 ( Figure 4c ). These results indicate that RA-induced decrease in p45
Skp2 and Cks1 protein levels involves post-transcriptional mechanisms.
We also investigated whether p45 Skp2 is itself a substrate for proteasomal degradation, as recently suggested (Wirbelauer et al., 2000) , and whether RA may enhance p45
Skp2 degradation through the same pathway. As shown in Figure 4d , incubation with LLnL prevented 13-cis-RA-mediated p45
Skp2 downregulation, demonstrating that RA modulates p45 Skp2 levels through the ubiquitin pathway. Moreover, endogenous ubiquitinated forms of p45 Skp2 were also analysed by Western blotting in the presence or absence of the proteasome inhibitor LLnL. As shown in Figure 4e , no laddering of ubiquitinated forms of p45
Skp2 was detected in untreated cells, whereas ubiquitinated intermediates of the protein accumulated remarkably upon proteasome inhibition, thus confirming that p45
Skp2 levels are modulated through the ubiquitin pathway. After 13-cis-RA treatment, increased levels of ubiquitinated forms of p45 Skp2 were evident even in the absence of LLnL and accumulated drastically after incubation with LLnL (Figure 4e ), clearly indicating that RA markedly enhances p45
Skp2 ubiquitination. Furthermore, incubation of HDE-14 cells with LLnL (5 mM for 72 h) induced a strong increase in the levels of the Cks1 protein (Figure 4d ), indicating that, in LCLs, Cks1 is also regulated by proteasome-mediated degradation. Moreover, treatment with LLnL prevented 13-cis-RAinduced Cks1 downregulation, demonstrating that RA interferes with proteasomal degradation of the Cks1 protein. Similar findings were observed in DAA-3 cells (not shown).
Overexpression of p45
Skp2 inhibits the antiproliferative effect of RA To substantiate the role of RA-dependent p45 Skp2 downregulation in mediating the antiproliferative effect of these compounds, we verified whether enforced expression of p45
Skp2 is able to counteract RA-induced growth inhibition. To this end, we set up a system to induce adoptive expression of p45 Skp2 in B cells using the retroviral expression plasmid pBabe Puro. Considering that in LCLs we repeatedly verified a very low efficiency of infection, we induced ectopic p45
Skp2 expression in the DG75 Burkitt lymphoma B cell line in which RA recapitulates all the cellular and biochemical events observed in LCLs, including the G0-G1 cell cycle arrest and p27
Kip1 upregulation (Cariati et al., 2000) . As shown in Figure 5a , DG75 cells infected with the pBabe-Skp2 vector showed a strong upregulation of p45
Skp2 protein levels and this correlated with a decreased p27 Kip1 expression. We then determined the effects of p45 Skp2 overexpression on DG75 cell proliferation and p27 Kip1 protein levels. When compared to control cultures, DG75 cells overexpressing p45
Skp2 showed a markedly decreased response to RA-induced growth inhibition at both 1 and 10 mM drug concentrations (Figure 5c ). Moreover, we found that overexpression of p45 Skp2 abolished the accumulation of p27
Kip1 observed in DG75 cells following RA treatment (Figure 5b ). These findings demonstrate that p45
Skp2 levels are an important regulator of p27
Kip1 upregulation induced by RA in B cells.
RA induces nuclear accumulation of p27 Kip1
Since p27
Kip1 protein expression may be also regulated at the level of intracellular transport, we investigated Kip1 in LCLs. Analysis of nuclear and cytoplasmic protein extracts by immunoblotting showed that, in HDE-14 and DAA-3 cells exposed to the vehicle alone, p27
Kip1 is located in both the nucleus and cytoplasm, whereas 13-cis-RA induced a strong nuclear accumulation of the protein (Figure 6a ). To define the subcellular localization of the p27 Kip1 degradation machinery in LCLs, the expression of SCF Skp2 complex components was then investigated by Western blotting in nuclear and cytoplasmic fractions. As shown in Figure 6b , the p19 Skp1 , Cks1 and Cul-1 SCF Skp2 components were mainly located in the cytoplasm of HDE-14 cells, whereas p45
Skp2 was present in both the nucleus and cytoplasm. These findings were confirmed by immunofluorescence staining and confocal microscopy ( Figure 6c ). To verify whether ubiquitination of p27 Kip1 occurs in the cytoplasm of LCLs, subcellular localization of p27 Kip1 -ubiquitinated forms was analysed in nuclear and cytoplasmic fractions of HDE-14 cells treated with LLnL. The analysis showed that p27 Kip1 -ubiquitinated forms are predominantly cytoplasmatic (Figure 6d) , consistent with the subcellular localization of the SCF Skp2 complex and with the cytoplasmic location of the proteasome machinery that degrades p27 Kip1 in LCLs. These findings are also in keeping with the observation that the cell extracts used for in vitro degradation assay were mainly cytoplasmatic (Figure 1c) , confirming that p27
Kip1 protein degradation by the 26S proteasome occurs in the cytoplasm of LCLs.
Inhibition of CRM1-dependent nuclear export induces p27
Kip1 nuclear accumulation and prevents the degradation of the protein
The finding that in RA-treated LCLs p27
Kip1 accumulates in the nucleus whereas the degradation of the protein occurs in the cytoplasm prompted us to investigate the effects of RA on intracellular trafficking of p27 Kip1 . Incubation of HDE-14 cells with LMB, an inhibitor of CRM1-dependent nuclear export (Wolff et al., 1997; Kudo et al., 1998) blocked the translocation of p27
Kip1 to the cytoplasm, as shown by Western blotting (Figure 7a ) and immunofluorescence analysis (Figure 7b ), indicating that, in LCLs, p27 Kip1 is exported from the nucleus through a CRM1-dependent mechanism. Notably, treatment with LMB not only blocked the translocation of p27
Kip1 but also prevented the degradation of the protein, as shown by the persistence of p27 Kip1 nuclear accumulation up to 24 h in the presence of LMB (Figure 7a ). Similar results were also observed with DAA-3 cells and DG75 cells (not shown). These findings indicate that nuclear export of p27
Kip1 is required for proteasome-mediated degradation of the protein.
p45
Skp2 but not p38 Jab1 is likely involved in CRM1-dependent nuclear export of p27 Kip1 p27
Kip1 trafficking in LCLs was analysed in more detail by investigating the possible involvement of p38 Jab1 , a shuttle protein that was shown to direct p27
Kip1 from the nucleus to the cytoplasm in other cellular systems (Tomoda et al., 1999 (Tomoda et al., , 2002 . As shown in Figure 8a , HDE-14 cells contained high levels of the p38 Jab1 protein, which however were unaffected by RA treatment. Western blot analysis of p38 Jab1 , carried out in nuclear and cytosolic fractions of HDE-14 cells, showed a mainly cytoplasmic localization of the protein in both control and RA-treated cells (Figure 8a ), and this distribution was not affected by LMB treatment. Moreover, confocal microscopy analysis confirmed that LMB did not induce nuclear accumulation of p38 Jab1 (Figure 8b ). These findings seem to exclude the possibility that p38 Jab1 could play a major role in regulating p27
Kip1 nuclear export in the LCL system. Consistently, immunoprecipitation experiments failed to reveal any interaction between p27
Kip1 and p38 Jab1 (data not shown).
The observation that p45
Skp2 has both nuclear and cytoplasmic distribution in LCLs suggested the possibility that this protein may be involved in p27
Kip1 nuclear export. The specific interaction between p27 Kip1 and p45
Skp2 was then analysed in nuclear and cytoplasmic extracts of HDE-14 cells. Immunoprecipitation experiments showed that, in untreated cells, p27 Kip1 is associated with p45
Skp2 both in the nucleus and the cytoplasm, whereas no interaction between p27 Kip1 and p45 Skp2 was observed after 13-cis-RA treatment (Figure 9a) . Interestingly, we found that LMB treatment markedly increased the levels of p45
Skp2 within the nuclei of HDE-14 cells at the expense of the cytoplasmic pool of the protein (Figure 9b) . Moreover, immunofluorescence analysis and confocal microscopy demonstrated that p45
Skp2 co-localized with the nuclear exportin CRM1 (Figure 10 ). These findings are consistent with the possibility that p45
Skp2 may be involved in the CRM1-dependent nuclear export of p27 Kip1 .
Discussion
We have previously demonstrated that the antiproliferative effect exerted by RA isomers in immortalized and neoplastic B lymphocytes is associated with the ability of these compounds to induce p27
Kip1 protein accumulation, which results in G0/G1 arrest (Zancai et al., 1998; Cariati et al., 2000) . The results of the present study indicate that, in LCLs, the ubiquitinproteasome pathway is involved in regulating the turnover of p27 Kip1 Kip1 is a crucial step for the ubiquitination and subsequent degradation of the protein (Muller et al., 1997; Sheaff et al., 1997; Vlach et al., 1997; Montagnoli et al., 1999; Tsvetkov et al., 1999) . In particular, phosphorylation of p27 Kip1 at Thr187 is required for the binding to p45
Skp2 of the SCF Skp2 ubiquitin E3 ligase complex . We herein demonstrate that RA treatment is associated with a decrease in the amount of p27 Kip1 phosphorylated at Thr187, consistent with the suppressed cyclinE/Cdk2 kinase activity observed in RAtreated LCLs (Zancai et al., 1998) . Nevertheless, RA did not affect the global pattern of p27 Kip1 phosphorylation, particularly the levels of pSer10-p27 , as disclosed by 2D-IEF experiments, indicating that mechanisms other than altered phosphorylation of the protein probably underlie RA-induced p27
Kip1 upregulation. The finding that RA inhibits p27
Kip1 ubiquitination prompted us to verify whether RA is able to modulate the expression of components of the SCF Skp2 complex. We herein provide evidence indicating that the stabilization of p27
Kip1 observed in RA-treated LCLs is the likely are markedly downregulated after exposure to RA, a phenomenon that is probably responsible for the impaired ubiquitination of p27 Kip1 observed in RAtreated cells. Unlike the SCF Skp2 components Skp1, Roc1/Rbx1 and Cul-1, whose levels do not change significantly during the cell cycle, the expression of p45
Skp2 and Cks1 is cell cycle regulated (Lisztwan et al., 1998; Michel and Xiong, 1998; Ohta et al., 1999) . In particular, in most cellular systems, the mRNA of both p45 Skp2 and Cks1 is absent during G0/G1 and accumulates at the G1/S boundary, when a rapid degradation of p27 Kip1 is required (Richardson et al., 1990) . The downregulation of p45
Skp2 and Cks1 observed in RAtreated LCLs, however, does not merely reflect the fact that RA arrests these cells in G0/G1. In fact, p45
Skp2 and Cks1 protein expression decreases early (12 h) after RA treatment, invariably before the onset of p27 Kip1 upregulation and the occurrence of growth arrest (Figure 4b ). In particular, the role of RA-induced p45
Skp2 downregulation in mediating the antiproliferative effects exerted by RA in B lymphocytes is further supported by our findings that enforced p45
Skp2 expression in DG75 cells prevented p27
Kip1 protein accumulation and induced resistance to RA treatment. Our results also indicate that RA downregulates p45
Skp2 expression by post-transcriptional mechanisms involving an Skp1 , Cks1 and Cul-1 SCF Skp2 components were mainly located in the cytoplasm of HDE-14 cells, whereas p45 Skp2 was present in both the nucleus and cytoplasm. (d) Ubiquitinated proteins are present both in the nucleus and cytoplasm, whereas p27
Kip1 -ubiquitinated forms are predominantly cytoplasmatic. p27
Kip1 protein was immunoprecipitated from nuclear and cytoplasmic fractions of HDE-14 cells untreated (NT), treated with LMB or LLnL for 7 h. The same analysis was carried out in nuclear and cytoplasmic protein extracts (50 mg). The presence of ubiquitinated proteins was visualized by immunoblotting with antiubiquitin antibody Figure 7 Inhibition of CRM1-dependent nuclear export blocks the translocation of p27
Kip1 to the cytoplasm and prevents its degradation. (a) HDE-14 cells were grown in the presence of DMSO, 13-cis-RA (72 h) or LMB (7 and 24 h). Nuclear and cytoplasmic fractions (30 mg) were analysed by immunoblotting with p27
Kip1 antibody. (b) RA and LMB induce nuclear accumulation of p27 Kip1 . Immunofluorescence staining shows that in HDE-14 cells exposed to the vehicle alone (DMSO), p27
Kip1 is located in both the nucleus and cytoplasm, whereas treatment with 13-cis-RA (72 h) or LMB (7 h) induced a strong nuclear accumulation of the protein increased ubiquitination and degradation of the protein by the proteasome machinery. These findings are in keeping with those recently reported by others, indicating that ATRA promotes ubiquitination and degradation of p45
Skp2 and cyclin D1 in breast cancer cell lines (Dow et al., 2001) .
Recently, Hattori et al. (2003) provided evidence indicating that the expression of Cks1 protein may be regulated not only transcriptionally but also at the posttranscriptional level via the ubiquitin-proteasome pathway in a cell cycle-dependent manner (Hattori et al., 2003) . Furthermore, Nakamura et al. (2003) reported that RA induces cell cycle arrest in neuroblastoma cell lines by decreasing the levels of the N-myc mRNA and protein and stabilizing p27 Kip1 . In this cellular system, RA also induced a downregulation of p45
Skp2 that was, however, not associated with changes in Cks1 expression levels (Nakamura et al., 2003) . In the present study, we demonstrate that, in LCLs, degradation of Cks1 protein was markedly inhibited by proteasome inhibitors, confirming that the Cks1 protein is regulated via the ubiquitin-proteasome pathway. However, unlike what was reported by Nakamura et al. (2003) in neuroblastoma cells, we herein show that RA decreases Cks1 protein levels by increasing proteasome-dependent degradation of the protein. These results were confirmed in other neoplastic B cell lines, including those derived from patients with Burkitt's lymphoma or mantle cell lymphoma (data not shown), indicating that RA-induced downregulation of both p45
Skp2 and Cks1 is probably a general phenomenon in B lymphocytes. Nevertheless, the real contribution of RA-induced Cks1 downregulation to B cell growth inhibition remains to be elucidated, also considering our finding that ectopic expression of p45 Skp2 alone induces resistance to the antiproliferative effects of RA. Whether RA-induced Cks1 downregulation is the consequence of a feedback mechanism or is rather part of a common negative growth regulatory pathway that functions by limiting the levels of both p45
Skp2 and Cks1 constitutes an attractive issue that deserves to be addressed by further studies. Skp2 and p27 Kip1 . While in untreated cells, p27
Kip1 is associated with p45 Skp2 both in the nucleus and the cytoplasm, there is no interaction between p27
Kip1 and p45 Skp2 after exposure to RA. HDE14 cells were treated with 13-cis-RA (72 h) and total cell extracts, nuclear and cytoplasmic fractions were prepared in the presence of okadaic acid. p27
Kip1 was immunoprecipitated from 1 mg of each fraction followed by immunoblotting with p45
Skp2 antibody. The corresponding levels of immunoprecipitated p27
Kip1 are also shown, confirming that nuclear and cytoplasmic compartments have different levels of p27
Kip1 . (b) LMB induces nuclear accumulation of p45
Skp2 . HDE-14 cells were incubated with DMSO, 13-cis-RA (72 h), or LMB (7 h) and p45
Skp2 localization was analysed by immunofluorescence staining and confocal microscopy Both the function and turnover of p27
Kip1 are strictly dependent on the subcellular localization of the protein.
In untreated LCLs, p27 Kip1 -ubiquitin intermediates were found exclusively in the cytoplasmic fraction, the subcellular compartment where the SCF Skp2 components Cul-1, p19
Skp1 and Cks1 are also located, indicating that ubiquitination and proteasome-dependent degradation of p27
Kip1 requires its cytoplasmic re-localization. Conversely, in cells growth-arrested by RA, p27
Kip1 is almost exclusively located within the nucleus where the protein can exert its activity as a CDK inhibitor. These findings are consistent with the possibility that RA could also interfere with the intracellular trafficking of the protein by preventing its translocation to the cytoplasm. In analogy with observations in other cellular systems, p27
Kip1 is exported from the nucleus through a CRM1-dependent mechanism in LCLs also. Notably, LCL treatment with LMB not only blocked the translocation of p27
Kip1 to the cytoplasm but also prevented the degradation of the protein, supporting the existence of a link between p27
Kip1 turnover and nuclear export.
Recent evidence indicates that phosphorylation of p27 Kip1 on Ser10 is required for its binding to CRM1 and subsequent nuclear export, contributing thus to regulate p27
Kip1 stability (Ishida et al., , 2002 . These studies also showed that Ser10 is the major phosphorylation site of p27 Kip1 , accounting for 70% of the total extent of p27 Kip1 phosphorylation. In fact, 2D analysis usually shows two main isoforms of the protein: pSer10-p27 Kip1 and unphosphorylated p27
Kip1 (Ishida et al., , 2002 . The present study confirms that Ser10 is the major p27
Kip1 phosphorylation site in LCLs also and demonstrates that RA has no effect on the levels of pSer10-p27 Kip1 , ruling out a possible inolvement of Ser10 phosphorylation in RA-induced p27
Kip1 re-localization. Little is currently known about the biochemical mechanisms regulating the intracellular trafficking of p27 Kip1 in different cellular backgrounds. Available evidence indicates that forced expression of the putative shuttle protein p38 Jab1 induces exportation of p27
Kip1 from the nucleus to the cytoplasm in a manner sensitive to inhibitors of both CRM1-dependent nuclear export and proteasome (Tomoda et al., 1999 (Tomoda et al., , 2002 . In LCLs, however, LMB did not induce nuclear accumulation of p38 Jab1 and we failed to reveal any interaction between p27
Kip1 and p38
Jab1
. These findings, together with the lack of direct association between p27
Kip1 and CRM1 (not shown), indicate that a shuttle protein different from p38 Jab1 probably mediates CRM1-dependent nuclear export of p27 Kip1 in LCLs. Interestingly, our results suggest that p45
Skp2 could be involved in this process. In fact, we have found that (i) p45
Skp2 has both nuclear and cytoplasmic distribution in LCLs; (ii) p27
Kip1 is associated with p45
Skp2 both in the nucleus and in the cytoplasmic compartments; (iii) treatment with LMB induced a marked accumulation of p45
Skp2 within the nuclei of LCLs at the expense of the cytoplasmic pool of the protein; and (iv) p45
Skp2 co-localized with the exportin CRM1. This possibility is also supported by the finding that the amino-acid sequence of p45 Skp2 contains several potential leucine-rich NES, which could mediate a direct binding of p45 Skp2 to CRM1 (not shown). A thorough analysis of the functional relevance of these putative NES is however required to conclusively demonstrate that p45
Skp2 directly mediates a CRM1-dependent shuttling of p27
Kip1 in these cells. Elucidation of this issue will also allow a better understanding of the still poorly defined link between nuclear export, ubiquitination and proteasome-dependent degradation of p27 Kip1 . The possible involvement of p45 Skp2 in the nuclear export of p27 Kip1 strengthens the relevance of RA-induced p45
Skp2 downregulation in mediating the stabilization of p27 Kip1 . In fact, RA treatment would deprive the cells not only of a key component of the SCF Skp2 complex targeting phosphorylated p27
Kip1 for ubiquitination but also of a protein involved in the relocalization of p27
Kip1 to the cytoplasm, where its proteasome-dependent degradation occurs.
The identification of p45 Skp2 and Cks1 as downstream targets of RA constitutes an important step in our understanding of the mechanisms underlying the antiproliferative activity of these compounds in LCLs. p45
Skp2 is overexpressed in many aggressive tumors, including several lymphoma histotypes, accounting for the enhanced p27
Kip1 degradation observed in most of these cases (Zhang et al., 1995; Esposito et al., 1997; Loda et al., 1997; Latres et al., 2001; Chiarle et al., 2002; Lim et al., 2002) . Similarly, given its role in promoting p27
Kip1 proteolysis, Cks1 could also contribute to the malignant phenotype, as suggested by recent data indicating that the overexpression of Cks1 detected in the blastoid variant of mantle cell lymphoma likely contributes to the highly malignant behavior of these tumors (De Vos et al., 2003) . On these grounds, our findings that RA downregulates both p45
Skp2 and Cks1 in LCLs provide the rational background to verify whether RA exerts similar effects also in B cell lymphomas characterized by a constitutively high p27 Kip1 -specific degradation activity.
Materials and methods
Cell lines, culture conditions and reagents
Establishment and characterization of the human EBVimmortalized LCLs, HDE-14 and DAA-3 have been previously described (Pomponi et al., 1996) . LCLs were cultivated in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated fetal calf serum (Gibco), 100 U/ml penicillin, 100 mg/ml streptomycin and 20 mM L-glutamine and maintained in a humidified 5% CO 2 incubator at 371C. Cultures were re-fed after 3 days and passaged weekly. 13-cis-RA (Sigma St Louis, MO, USA) was prepared as 10 À1 M stock in dimethylsulfoxide (DMSO) and diluted in the culture medium so that the final concentration of the solvent was p0. 01% (v/v) . In all the experiments, 13-cis-RA was used at 1 mM. The proteasome inhibitors MG132 (Z-Leu-Leu-Leu-CHO, Biomol Research, Plymouth Meeting, CA, USA), LLnL (N-acetyl-Leu-Leunorleucinal, Sigma) and clasto-Lactacystin b-lactone (Alexis Biochemicals, Lausen, Switzerland) were prepared in DMSO and used at the concentration of 50 mM unless otherwise specified. The CRM1 inhibitor Leptomycin B (Sigma) was used at a final concentration of 20 ng/ml. The MAPK inhibitor UO126 (Calbiochem) was used at a final concentration of 20 mM.
Cell proliferation assays
Proliferation assays were performed in 96-well 
Retrovirus infection
DG75-Skp2 cells were generated by retroviral infection, as previously described (Seger et al., 2002) . Briefly, pBabe-Puro Skp2 (a kind gift from H Zhang) and pBabe-Puro-GFP were used to transfect the amphotropic packaging cell line LinX-A (Hannon et al., 1999) . Transfection was performed by the calcium phosphate method. At 72 h post-transfection, viral supernatants were collected, filtered, supplemented with 4 mg/ml polybrene and used to infect DG75 cells. After infection, cells were selected with puromycin (1 mg/ml) for 5 days. Effective infection was confirmed by Western blot analysis.
Antibodies
Antibodies to p27
Kip1 (clone 57), CRM1 and topoisomerase IIa were from BD Transduction Laboratories (Lexington, LY, USA); p27 Kip1 (C-19), p27 Kip1 (F-8, agarose conjugated), ubiquitin (P4D1), p45
Skp2 (H-435), p19 Skp1 (H-163), Cks1 (FL-79), p53 (DO-1), Cdk2 (M2), p38 Jab1 (FL-334) and phosphop27 Kip1 S10 antibodies were from Santa Cruz (Santa Cruz Biotechnologies, CA, USA); phospho-p27 Kip1 (Thr187) antibody was from Zymed; Cullin-1 antibody from Biosource International (Camarillo, CA, USA); actin antibody was from Amersham Pharmacia and tubulin antibody was from BD Pharmingen (San Diego, CA, USA).
Extract preparation, immunoprecipitation and Western blotting
Whole-cell lysates were prepared in lysis buffer (50 mM TrisHCl, pH 7.5; 150 mM NaCl; 2 mM EDTA; 2 mM EGTA; 2 mM sodium orthovanadate; 25 mM b-glycerolphosphate; 25 mM NaF; 1 mM PMSF; 1 mM okadaic acid; 5 mg/ml leupeptin; 5 mg/ml aprotinin; 0.2% Triton X-100; 0.3% NP40) and lysed for 30 min on ice. Total protein extracts were obtained by centrifugation at 16 000 g for 30 min and protein concentration was determined by Bio-Rad protein Assay. For nuclear and cytoplasmic extract preparation, cells were incubated in icecold cell lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 5 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mM okadaic acid, 0.1% NP40). Incubation was continued for 30 min, checked microscopically for cell lysis and then centrifuged at 600 g for 5 min at 41C. The supernatant (cytoplasmic fraction) was recovered and the pellet (nuclear fraction) was re-suspended in ice-cold extraction buffer (20 mM HEPES, 400 mM NaCl, 1 mM EDTA, 0.5 mM PMSF, 5 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mM okadaic acid, 1% NP40) and lysed for 2 h on ice. Nuclear extracts were clarified at 16 000 g for 30 min and stored at À801C. Proteins were fractionated using SDS-PAGE and transferred onto nitrocellulose membranes. Immunoblotting was performed using the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech, Uppsala, Sweden). In immunoprecipitation studies, 500-1000 mg of proteins was incubated overnight with 1 mg of appropriate antibody and 50 ml of protein A sepharose CL4B (Amersham Pharmacia Biotech), centrifuged and washed three times with lysis buffer. Proteins were eluted with Laemmli sample buffer and fractionated using SDS-PAGE, and Western blots were performed.
2D-IEF and phosphatase treatment
Cells were lysed in ice cold lysis buffer and p27
Kip1 immunoprecipitates were denatured in 8 M urea buffer, loaded onto immobilized nonlinear pH gradient (3-10) IEF strips, and focused for 2000 Vh using the Zoom IPG Runner apparatus from Invitrogen. IEF strips were equilibrated in LDS sample buffer (Invitrogen) with 10 mM DTT for 15 min and in LDS sample buffer with 125 mM iodoacetamide for 15 min before loading on 4-12% gradient Bis-Tris gel electrophoresis. For phosphatase treatment, immunoprecipitated p27
Kip1 was incubated with 20 U calf intestinal phosphatase (Roche, Milan) in 20 ml of reaction buffer for 5 h at 371C. Proteins from SDSpolyacrylamide gels were transferred onto nitrocellulose membrane and subjected to immunoblot analysis with antibodies to p27
Kip1 or pSer10-p27
Kip1
.
In vitro degradation assay
Cells were gently lysed in ice-cold 10 mM Tris-HCl buffer (pH 8) by passing through a 22-gauge needle on ice. After centrifugation at 16 000 g at 41C for 10 min, supernatants were collected, analysed for protein concentration with Bradford's method, aliquoted and stored at À801C. In total, 60 mg of lysates was added to 50 ml of reaction buffer containing 50 mM Tris-HCl (pH 8.3), 5 mM MgCl 2 , 2 mM DTT, 5 mM ubiquitin (Sigma), 3.5 mU/ml creatine kinase, 10 mM creatine phosphate, and 2 mM ATP. In total, 50 ng of in vitro translated p27
Kip1 protein (prepared from p27 Kip1 cDNA cloned in the pcDNA3 vector, obtained from Dr H Zhang, and translated using the rabbit reticulocyte lysate TNT kit from Promega, Milan, Italy) was added to each sample. p27
Kip1 alone in 50 ml reaction buffer was used as positive control. As additional controls, lysate samples (60 mg) in 50 ml reaction buffer containing 50 ng p27 Kip1 were incubated with 40 mM of the proteasome inhibitor MG132 (Biomol Research) or the vehicle alone (DMSO). After 6 h of incubation at 371C, aliquots of 3 ml were removed at desired time points, added to 30 ml of Laemmli buffer and loaded on 12% SDS-PAGE gels and analysed by immunoblotting with p27
Kip1 antibody. Disappearance of recombinant p27 Kip1 bands was quantitated by densitometric scanning (Bio Rad GS-670, Milan, Italy).
RNA extraction and Northern Blotting
Total cellular RNA was isolated by the guanidinium isothiocyanate method described by Chomczynski and Sacchi (1987) . RNA samples (15 mg) were electrophoresed in 1% agarose gels containing 2.2 M formaldeyde, transferred to Pall Biodyne B membranes (Pall, Portsmouth, UK) by electroblotting, and baked for 2 h at 801C in vacuo. Hybridizations were performed at 371C for 18 h in a buffer containing 50% formamide with p27 Kip1 , p45
Skp2 and Cks1 specific probes labeled with [a- 32 P]dCTP. p27
Kip1
, p45 Skp2 and Cks1 DNA fragments were obtained from the HDE-14 LCL by RT-PCR using the following primers: 5 0 -ATG TCA AAC GTG CGA GTG TCT AAC G-3 0 (p27 Kip1 sense) and 5 0 -TTA CGT TTG ACG TCT GAG GCC A-3 0 (p27 Kip1 antisense); 5 0 -TCA AGG GGT GAT TGC CTT CCG-3 0 (p45 Skp2 sense) and 5 0 -CTG AGA CAT GCG CAA CAG CCA-3 0 (p45 Skp2 antisense); 5 0 -ATG TCA TGC TGC CCA AGG A-3 0 (Cks1 sense) and 5 0 -GCT ATG GTG GTG GTG GCT CT-3 0 (Cks1 antisense). PCR conditions were as follows: for p27 Kip1 , denaturation at 951C for 1 min, annealing at 601C for 1 min and 721C for 1 min (30 cycles); for p45 Skp2 , denaturation at 951C 1 min, annealing at 571C 1 min and 721C 1 min (28 cycles); for Cks1, denaturation at 951C for 1 min, annealing at 541C 1 min and 721C 1 min (27 cycles). After hybridization, membranes were washed twice for 5 min in 2 Â standard saline citrate (SSC) at room temperature, twice for 30 min in 2 Â SSC-1%SDS at 651C and twice for 30 min in 0.1 Â SSC at room temperature. The filters were then autoradiographed using intensifying screens at À701C. RNA integrity and loading was assessed by 28S and 18S rRNA levels. Levels of gene expression were determined by densitometric scanning.
Immunofluorescence analysis
Cells were washed with PBS, fixed for 15 min in 3% paraformaldehyde in PBS, rinsed twice with PBS and incubated for 40 min in 0.1% NP40 in PBS. After three washes in PBS/0.1% BSA, incubations with rabbit and mouse primary antibodies (diluted 1 : 100) were carried out for 60 min at 371C in a humidified atmosphere. After three washes in PBS, secondary antibodies diluted 1 : 100 (anti-mouse and anti-rabbit Alexa Fluor 488 and Alexa Fluor 546, Molecular Probes, Eugene, OR, USA) were incubated for 45 min at room temperature. Cells were washed in PBS, mounted in Vectashield (Vector Laboratories) and analysed by confocal fluorescence microscopy (UltraVIEWt Live Cell Imager, Perkin Elmer, Boston, MA, USA).
